Literature DB >> 10092781

Dissociation between IFN-alpha-induced anti-viral and growth signaling pathways.

T Arora1, G Floyd-Smith, M J Espy, D F Jelinek.   

Abstract

The ability of IFN-alpha to induce an anti-viral state in a wide variety of cell types as well as to inhibit cellular growth has long been appreciated. It is less clear, however, whether both these effects lie downstream of a common signaling pathway. In this study we have taken advantage of an atypical human myeloma cell line (KAS-6/1) displaying a dramatic proliferative response to IFN-alpha in an effort to resolve the signaling requirements for IFN-alpha-induced anti-viral and growth regulatory effects. Thus, we have analyzed the ability of IFN-alpha to induce a number of known receptor-initiated events in this cell line and have compared these responses with those exhibited by a cell lineage- and maturation stage-matched myeloma cell line (ANBL-6) that displays typical IFN-alpha responsiveness. Despite the widely contrasting effects of IFN-alpha on cellular proliferation, IFN-alpha was shown to be comparable in its ability to induce the expression of early response genes as well as induce resistance to viral infection in both cell lines. By contrast, the effects of IFN-alpha on the activation of mitogen-activated protein kinase (MAPK) were strikingly distinct. Finally, although inhibition of MEK and MAPK activation had no effect on the induction of the anti-viral response, it completely blocked IFN-alpha-stimulated proliferation of the KAS-6/1 cells. In summary, our analysis of the role of the MAPK and anti-viral signaling pathways using these two cell lines suggests that the anti-viral and growth regulatory effects of IFN-alpha display a differential requirement for activation of the MAPK pathway.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10092781

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Differential effects of interferon alpha-2b and beta on the signaling pathways in human liver cancer cells.

Authors:  Kazuya Matsumoto; Jun-ichi Okano; Yoshikazu Murawaki
Journal:  J Gastroenterol       Date:  2005-07       Impact factor: 7.527

2.  Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.

Authors:  Subbiah Elankumaran; Vrushali Chavan; Dan Qiao; Raghunath Shobana; Gopakumar Moorkanat; Moanaro Biswas; Siba K Samal
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

3.  IFN-α and lipopolysaccharide upregulate APOBEC3 mRNA through different signaling pathways.

Authors:  Harshini V Mehta; Philip H Jones; Jerrold P Weiss; Chioma M Okeoma
Journal:  J Immunol       Date:  2012-09-12       Impact factor: 5.422

4.  Differential effect of murine alpha/beta interferon transgenes on antagonization of herpes simplex virus type 1 replication.

Authors:  Peter Härle; Vanessa Cull; Martin-Paul Agbaga; Robert Silverman; Bryan R G Williams; Cassandra James; Daniel J J Carr
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

5.  Interferon alpha regulates MAPK and STAT1 pathways in human hepatoma cells.

Authors:  Lan-Juan Zhao; Xian Hua; Sheng-Fei He; Hao Ren; Zhong-Tian Qi
Journal:  Virol J       Date:  2011-04-06       Impact factor: 4.099

6.  Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism.

Authors:  F Romerio; A Riva; D Zella
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

7.  DMO-CAP inhibits influenza virus replication by activating heme oxygenase-1-mediated IFN response.

Authors:  Ming Zhong; Huiqiang Wang; Linlin Ma; Haiyan Yan; Shuo Wu; Zhengyi Gu; Yuhuan Li
Journal:  Virol J       Date:  2019-02-20       Impact factor: 4.099

8.  PML-II regulates ERK and AKT signal activation and IFNα-induced cell death.

Authors:  Xueqiong Meng; Yixiang Chen; Salvador Macip; Keith Leppard
Journal:  Cell Commun Signal       Date:  2021-07-02       Impact factor: 5.712

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.